“…We have previously shown that, within the time frame of the HAE assay, lipid-free apoA-I predominantly exchanges onto smaller HDL particles ( 31 ). Furthermore, in vitro studies of HDL remodeling in the absence of apoB particles catalyzed by LCAT ( 42,43 ), PLTP ( 44,45 ), or effl ux capacity included HAE, gender, age, HDL-C, triglycerides, and statin use, and explained over 80% of the J774 effl ux variance, with HDL-C ( b = 0.884, P < 0.0001, 59% model variance explained) and HAE ( b = 0.202, P = 0.031, 26% model variance explained) as the most signifi cant contributors to the model ( Table 3 ). The model for ABCA1-specifi c effl ux capacity explained over 50% of the variance, with HAE as the strongest predictor ( b = 0.342, P = 0.015, 24% explained) followed by HDL-C ( b = 0.390, P = 0.01, 23% explained).…”